Arvinas Inc Gains FDA Approval for VEPPANU PROTAC Drug
NEW HAVEN, Conn., May 1, 2026 Arvinas, Inc., in collaboration with Pfizer Inc., announced that the U.S. Food and...
Phase 3 trial
Advertisement
Rhythm Pharmaceuticals Secures EU Approval for IMCIVREE
BOSTON, MA, May 1, 2026 Rhythm Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for IMCIVREE®...
Kodiak KSI-101 Shows Strong MESI Clinical Trial Results
Palo Alto, California, United States | May 1, 2026 Kodiak Sciences Inc. has announced new clinical and pipeline advancements...
Vanda Launches NEREUS First Motion Sickness Drug
Washington, United States | May 1, 2026 Vanda Pharmaceuticals Inc. has announced the U.S. commercial availability of NEREUS™ (tradipitant),...
Pfizer ELREXFIO Phase 3 Trial Improves Survival Outcomes
New York, United States | April 29, 2026 Pfizer Inc. has reported positive Phase 3 clinical trial results for...
Advertisements
Sydnexis, Inc. Advances SYD-101 Data in Myopia Trial
DEL MAR, California, May 1, 2026 Sydnexis, Inc. announced it will present new Phase 3 STAR trial data for...
BeOne Medicines Gains FDA Priority Review for TEVIMBRA
SAN CARLOS, CALIFORNIA, April 29, 2026 BeOne Medicines has announced that the U.S. Food and Drug Administration (FDA) has...
OS Therapies Secures EMA Review for OST-HER2 Drug
NEW YORK, New York, April 30, 2026 OS Therapies announced that the European Medicines Agency (EMA) has initiated a...
Theradaptive Gains FDA Approval for Regenerative Spine Therapy
FREDERICK, MARYLAND, April 30, 2026 Theradaptive has received U.S. Food and Drug Administration (FDA) authorization to advance its OASIS...
Immunome Files FDA NDA for Varegacestat in Tumors
BOTHELL, WASHINGTON, April 29, 2026 Immunome has announced the submission of a New Drug Application (NDA) to the U.S....
Advertisement
